Petrie J C, Jeffers T A, Robb O J, Scott A K, Webster J
Br Med J. 1980 Jun 28;280(6231):1573-4. doi: 10.1136/bmj.280.6231.1573.
The effect of once-daily atenolol, sustained-release oxprenolol (a new formulation of oxprenolol presented as a compressed tablet in a waxed matrix), and long-acting propranolol (a new formulation presented as spheriods in a capsule) was studied in a double-blind crossover trial in 23 carefully selected hypertensive outpatients. After a run-in period with matching placebo each patient received atenolol (100 mg/day), sustained-release oxprenolol (160 mg/day), long-acting propranolol (160 mg/day), and placebo according to a randomised sequence. After four weeks' treatment with sustained-release oxprenolol blood pressure in the two to four hours before the next dose was not significantly lower than after placebo. The effectiveness of atenolol and of the new formulation of propranolol in reducing blood pressure was confirmed. These results suggest that the present formulation of sustained-release oxprenolol should be reconsidered.
在一项双盲交叉试验中，对23名精心挑选的高血压门诊患者研究了每日一次阿替洛尔、缓释氧烯洛尔（一种以蜡质基质压制片形式呈现的氧烯洛尔新制剂）和长效普萘洛尔（一种以胶囊中球体形式呈现的新制剂）的效果。在使用匹配安慰剂的导入期后，每位患者按照随机顺序接受阿替洛尔（100毫克/天）、缓释氧烯洛尔（160毫克/天）、长效普萘洛尔（160毫克/天）和安慰剂。在用缓释氧烯洛尔治疗四周后，在下一次给药前两到四小时的血压并不显著低于使用安慰剂后。阿替洛尔和新制剂普萘洛尔降低血压的有效性得到了证实。这些结果表明，目前的缓释氧烯洛尔制剂应重新考虑。
